Left univentricular pacing for cardiac resynchronization therapy using rate-adaptive atrioventricular delay

Li-Jin PU1,2*, Yu WANG1,2*, Lu-Lu ZHAO2, Tao GUO1,2, Shu-Min LI1, Bao-Tong HUA1, Ping YANG1, Jun YANG1, Yan-Zhou LU2, Liu-Qing YANG3, Ling ZHAO1,2, Hai-Yun LUO4

1Department of Cardiology, the First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
2Institute of Cardiovascular Diseases of Yunnan Province, Kunming, Yunnan, China
3Cardiovascular Division and Lillehei Heart Institute, University of Minnesota, Minnesota, USA
4Department of Pharmacology, College of Basic Medicine, Kunming Medical University, Kunming, Yunnan, China

Abstract

Objective To evaluate left univentricular (LUV) pacing for cardiac resynchronization therapy (CRT) using a rate-adaptive atrioventricular delay (RAAVD) algorithm to track physiological atrioventricular delay (AVD).

Methods A total of 72 patients with congestive heart failure (CHF) were randomized to RAAVD LUV pacing versus standard biventricular (BiV) pacing in a 1:1 ratio. Echocardiography was used to optimize AVD for both groups. The effects of sequential BiV pacing and LUV pacing with optimized A-V (right atrio-LV) delay using an RAAVD algorithm were compared. The standard deviation (SD) of the S/R ratio in lead V1 at five heart rate segments (RS/S-SD5), defined as the “tracking index,” was used to evaluate the accuracy of the RAAVD algorithm for tracking physiological AVD.

Results The QRS complex duration (132 ± 9.8 vs. 138 ± 10 ms, P < 0.05), the time required for optimization (21 ± 5 vs. 50 ± 8 min, P < 0.001), the mitral regurgitant area (1.9 ± 1.1 vs. 2.5 ± 1.3 cm², P < 0.05), the interventricular mechanical delay time (60.7 ± 13.3 ms vs. 68.3 ± 14.2 ms, P < 0.05), and the average annual cost (13,200 ± 1000 vs. 21,600 ± 2000 RMB, P < 0.001) in the RAAVD LUV pacing group were significantly less than those in the standard BiV pacing group. The aortic valve velocity-time integral in the RAAVD LUV pacing group was greater than that in the standard BiV pacing group (22.7 ± 2.2 vs. 21.4 ± 2.1 cm, P < 0.05). The RS/S-SD5 was 4.08 ± 1.91 in the RAAVD LUV pacing group, and was significantly negatively correlated with improved left ventricular ejection fraction (LVEF) (Pearson’s r = −0.427, P = 0.009), and positively correlated with New York Heart Association class (Spearman’s r = 0.348, P = 0.037).

Conclusions RAAVD LUV pacing is as effective as standard BiV pacing, can be more physiological than standard BiV pacing, and can decrease the average annual cost of CRT.

J Geriatr Cardiol 2017; 14: 118–126. doi:10.11909/j.issn.1671-5411.2017.02.006

Keywords: Cardiac resynchronization therapy; Congestive heart failure; Left univentricular pacing; Rate adaptive atrio-ventricular delay

1 Introduction

The cost for treatment of congestive heart failure (CHF) is relatively higher than that for other cardiovascular diseases. Many CHF patients also have complete left bundle branch block (CLBBB), which can result in systolic inter-
The intrinsic atrioventricular delay (AVD) varies with the activity of the autonomic nervous system and heart rate (HR). Accordingly, rate-adaptive AVD (RAAVD) was developed to mimic physiological AVD, and to dynamically coordinate the filling from atrium to ventricle. However, use of a fixed, short AVD (100–120 ms) setting for biventricular capture in CRT, which abolishes the physiological AVD of the AV node (AVN), can impede physiological conduction in the AVN, thereby counteracting the benefit of standard BiV pacing.

Generally, right-sided conduction is normal in patients with CLBBB; therefore, there is no need for RV pacing in CRT. Studies have shown that maintaining intrinsic AVN conduction, with simultaneous LV pacing and elimination of RV pacing, can improve acute hemodynamics more effectively than standard BiV pacing. Thus, enabling fusion of intrinsic right bundle conduction with paced LV conduction, by tracking right-sided intrinsic AVD using an RAAVD algorithm, can be more physiological than standard BiV pacing, thereby increasing the response to CRT. This study evaluated the effect of LUV pacing for CRT using an RAAVD algorithm to track physiological AVD, in comparison with that for standard BiV pacing.

2 Methods

2.1 Patients

A total of 72 patients with congestive heart failure (CHF) were randomized to RAAVD LUV pacing versus standard BiV pacing in a 1:1 ratio. The study was performed at the first affiliated hospital of Kunming Medical University from July 2013 to December 2015. All patients had the following Class IA indications for CRT: (1) ischemic or non-ischemic cardiomyopathy; (2) New York Heart Association (NYHA) Class II, III, or ambulatory Class IV after optimal medical therapy for CHF; (3) sinus rhythm; (4) left ventricular ejection fraction (LVEF) ≤ 35%; and (5) CLBBB, with QRS complex > 150 ms. Standard medical therapy for CHF was given to all enrolled patients, which included administration of β-receptor antagonists, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and spironolactone. Informed consent for CRT was obtained. Basic demographic information, preimplantation CHF parameters, relevant CHF medications, and pacing lead locations were collected at subject enrolment. This study was conducted in accordance with the declaration of Helsinki, and conducted with approval from the Ethics Committee of Kunming medical University. Written informed consent was obtained from all participants.

Patients were excluded from the study if they had (1) life expectancy of less than one year, (2) cardiomyopathy due to reversible causes, (3) valvular disease, (4) hypertrophic obstructive cardiomyopathy, (5) second or third degree atrioventricular block, (6) atrial fibrillation, or a (7) PQ interval > 0.22 s.

2.2 CRT pacing system and pacemaker implantation

A CRT pacing system, according to operator preference, was implanted after informed consent was obtained. The devices used in this study included a three-chamber pacemaker/defibrillator (CRT-P/D) (Syncera C2TR01CRT, C174AWK CRT-D, Maximo II CRT-D, Insync sencyt 7298 CRT-D) and a dual-chamber pacemaker (Adapta ADDRL1/ADDRS1/ADDRR01, Sensia SED01/SED0R01, Relia RED01) (Medtronic; Minneapolis, MN, USA). Pacemaker implantation was performed according to a standard procedure. For a dual-chamber pacemaker, two J-type guidewires were inserted through the left subclavian vein into the inferior vena cava. The pacemaker pocket was formed through blunt fascial dissection. The peel-away introducer was advanced along a guidewire, and the electrode was advanced to the coronary sinus ostium, followed by balloon catheter placement for retrograde angiography. Then, LV conveyor systems were placed. Under X-ray guidance, a percutaneous transluminal coronary angioplasty guidewire was used to advance the LV electrode lead to a position in the left posterolateral cardiac vein where possible, or in an alternative posterior or lateral vein, and the right atrial electrode was placed in the right atrial appendage. The LV lead was placed for greatest spatial separation from the tip of the RV lead, with stable LV capture and without diaphragmatic capture at four times the threshold voltage. The LV electrode and right atrial electrode leads were connected to corresponding jacks on the pulse generator. For a three-chamber CRT-P/D, a RV lead was placed in the apex of the RV.

2.3 Measurement of QRS duration

The QRS duration was automatically measured by using a 12-lead ECG machine (Marquette; GE, USA) at a speed of 25 mm/s and a gain of 1 mv/10 mm) before and after CRT, optimized using current guidelines and RAAVD LUV pacing, respectively. The morphology of the QRS complex in lead V1, defined as the average amplitude of S and R waves, was used to characterize the degree of fusion between LV pacing and intrinsic excitation. A Holter ECG was recorded at follow-up, and the ratio of the amplitude of S and R waves (S/R ratio) was calculated at a heart rate (HR) of 60, 70, 80, 90, and 100 beats/min. For each patient in the RAAVD LUV pacing group, QRS duration and the amplitude of S and R were measured and averaged for three
consecutive beats using software calipers, and the S/R ratio was calculated. In this study, we defined standard deviation (SD) of the S/R ratio in lead V1 at five segments of HR ($R_{50}$-SD5) as the “tracking index,” which was used to evaluate the accuracy of the RAAVD algorithm for tracking physiological AVD at varying HRs.

2.4 Determination of PR interval at start and stop rate

A Holter ECG was recorded before CRT, and the HR and PR interval were used as dependent and independent variables, respectively, to establish a linear regression model. The start and stop rates were defined as the lower limit rate (LLR) and upper tracking rate (UTR), respectively. If the PR interval at the start and stop rates was not recorded by the Holter ECG, it could be calculated by using the linear regression model; the regression equation was defined as follows: $PR = a \times HR + b$, where $b$ is constant, $a$ is the partial regression coefficient, and HR is LLR or UTR.

2.5 Measurement of cardiac ultrasound indicators

A Vivid7 Color Doppler System (GE Medical, Milwaukee, WI, USA) was used to measure echocardiographic indicators. The results were analyzed at a core laboratory by a single experienced observer blinded to the study. First, left ventricular end-diastolic diameter was measured directly from the 2-dimensional parasternal long-axis view or from M-mode recordings, using the leading-edge technique. Second, Doppler sample volume was located at the level of the mitral ostium in an apical 4-chamber view. Third, LV outflow tract blood flow spectrum was analyzed by locating the partial regression coefficient, and VS is LLR or UTR.

2.6 Exercise tolerance

The 6-minute walk test distance was measured, and used to evaluate the improvement of exercise capacity.

2.7 A-V and V-V delay optimization in standard BiV pacing

A device programmer (CareLink model 2090; Medtronic) was used to interrogate and program the device. A-V and V-V delay were optimized at rest with the patient in the left lateral position after pacemaker implantation implantation, according to current guidelines. Sensed A-V interval (SAV) was used when the function of the sinus node was normal. First, BiV pacing mode (RV + LV) was programmed, and then the AVD was titrated in 10-ms steps. The atrio-LV delay was programmed first. The optimal AVD in standard BiV pacing was defined as the shortest AVD that could ensure the longest duration of ventricular filling, the largest stroke volume, the largest AVVTI, and minimization of mitral regurgitation (MR), with no truncation of the transmitial A wave, while ensuring paced ventricular activation.

2.8 AVD and V-R delay optimization in the RAAVD LUV pacing group

Atrial sense compensation (ASC) was measured as the time from onset of the A wave to atrial sense (AS) in the right atrial (RA) intracardiac electrogram (IEGM). In this study, the optimal interval between the RV and LV was defined as the V-R delay in the LUV pacing group. Prolonging AVD until ventricular sense (VS) showed on the IEGM, with AS- VS interval – ASC as the baseline interval, and progressive shortening by 10-ms steps. The optimal AVD (i.e., left-sided AVD) was that which achieved the maximal increase in AVVTI. Optimal V-R delay can be calculated as PR interval at optimization – (optimal AVD + ASC).

2.9 Programing steps for LUV pacing with RAAVD

Set start (60 beats/min) and stop rate (UTR). Set SAV for start and stop rate: start/stop rate SAV = PR interval at start/stop rate – (Optimal V-R delay + ASC) = {PR interval at start/stop rate – [PR interval at optimization – (optimal AVD + ASC)]} – ASC = Optimal AVD + (PR interval at start/stop rate – PR interval at optimization). Set PAV for start/stop rate (PAV = SAV for start/stop rate + ASC). The AVD was titrated until ventricular sensing (VS) was displayed on the marker channel of the programmer. LV-only pacing mode was programmed and RAAVD was set to ON. Echocardiographic evaluation of cardiac function was performed five minutes after programming. The times required for optimization in both groups were compared.

2.10 Estimation of device longevity

Device longevity was estimated for standard BiV and LUV pacing groups. The average cost of CRT was based on
the cost of the pacemaker system and device longevity. Efficacy of CRT was compared for LUV pacing with an RAAVD algorithm and standard BiV pacing.

2.11 Data analysis

All data were analyzed with SPSS 17.0 software. Baseline characteristics are expressed as mean and SD for continuous variables, and percentages for categorical variables. The chi-square test was used to analyze dichotomous variables. The means in the two groups were compared with a t-test if the data showed a normal distribution; if not, the Mann-Whitney U test was used. A linear regression model was used to analyze the correlation between PR interval and HR. Correlations between R-S/R-SD5 and improved LVEF (ΔLVEF), and between R-S/R-SD5 and NYHA class, were determined by Pearson and Spearman coefficients, respectively. A 2-tailed P value < 0.05 was considered statistically significant.

3 Results

3.1 Patient demographics

The preimplant characteristics of the 72 patients enrolled in the study are shown in Table 1. The baseline (pre-CRT) age, sex, exercise tolerance, PR intervals, NYHA class, and cardiac ultrasound indicators were not significantly different between RAAVD LUV pacing and standard BiV pacing groups (P > 0.05).

3.2 Follow-up results

After a mean follow-up duration of 13 months, the estimated device longevity in the RAAVD LUV pacing group (6.9 ± 0.3 years) was significantly longer than that in the standard BiV pacing group (3.7 ± 0.2 years, P < 0.001). The QRS duration (132 ± 9.8 vs. 138 ± 10 ms, P < 0.05), the time required for optimization (21 ± 5 vs. 50 ± 8 min, P < 0.001), the MRA (42.1 ± 8.2 vs. 44.2 ± 8.6, P = 0.293), and the average annual cost (13,200 ± 1,000 vs. 21,600 ± 2,000 RMB, P < 0.001) were significantly less in the RAAVD LUV pacing group than in the standard BiV pacing group. The AVVTI in the RAAVD LUV pacing group was greater than that in the standard BiV pacing group (22.70 ± 2.20 vs. 21.40 ± 2.10 cm, P < 0.05). The other variables were not significantly different between the groups (P > 0.05). Three patients in the RAAVD LUV pacing group and 4 in the standard BiV pacing group died (P > 0.05) (Table 2). Figures 1-4 show a patient in the RAAVD LUV pacing group who received a dual-chamber pacemaker (Relia RED01).

Table 1. Baseline characteristics.

| Variables       | Standard BiV pacing group (n = 36) | RAAVD LUV pacing group (n = 36) | P value |
|-----------------|-----------------------------------|--------------------------------|---------|
| Age, yrs        | 54 ± 13                           | 55 ± 14                         | 0.754   |
| Male            | 27 (75%)                          | 28 (77.8%)                      | 0.781   |
| Etiology        |                                   |                                 |         |
| DCM             | 30 (83.3%)                        | 31 (86.1%)                      | 0.743   |
| ICM             | 6 (16.7%)                         | 5 (13.9%)                       | 0.743   |
| NYHA Class      | 3.11 ± 0.57                       | 3.19 ± 0.58                     | 0.557   |
| II              | 4 (11.11%)                        | 3 (8.33%)                       | 0.5     |
| III             | 24 (66.67%)                       | 23 (63.9%)                      | 0.804   |
| IV              | 8 (22.2%)                         | 10 (27.8%)                      | 0.586   |
| PR interval, ms | 162 ± 12                          | 166 ± 12                        | 0.162   |
| QRS complex     |                                   |                                 |         |
| duration, ms    | 178 ± 19                          | 182 ± 20                        | 0.388   |
| LADD, mm        | 42.1 ± 8.2                        | 44.2 ± 8.6                      | 0.293   |
| LVDD, mm        | 74.6 ± 10.0                       | 76.2 ± 10.5                     | 0.514   |
| LVEF, %         | 0.28 ± 0.06                       | 0.27 ± 0.06                     | 0.292   |
| MRA, cm²        | 4.7 ± 1.3                         | 4.3 ± 1.2                       | 0.179   |
| AVVTI, cm       | 15.7 ± 2.2                        | 16.1 ± 2.2                      | 0.443   |
| E/A Pd, ms      | 207 ± 59                          | 218 ± 62                        | 0.443   |
| IVMD, ms        | 77.5 ± 13.2                       | 80.4 ± 13.4                     | 0.358   |
| Ts-SD12, ms     | 108 ± 19                          | 114 ± 20                        | 0.196   |
| 6MWT, m         | 350 ± 53                          | 344 ± 51                        | 0.626   |

Data were presented as mean ± SD or n (%). AVVTI: aortic velocity-time integral; BiV: biventricular; DCM: dilated cardiomyopathy; E/A Pd: E/A procedure duration; LADD: left atrial diastolic diameter; LUV: left univentricular; LVDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; ICM: ischemic cardiomyopathy; IVMD: Interventricular mechanical delay time; MRA: area of the mitral regurgitation; NYHA: New York Heart Association; RAAVD: rate adaptive atrio-ventricular delay; Ts-SD12: Standard deviation of time intervals of the 12 LV segments; 6MWT: 6-minute walk test.

R-S/R-SD5 was 4.08 ± 1.91 in the RAAVD LUV pacing group, and was significantly negatively correlated with improved LVEF (ΔLVEF) (Pearson’s r = -0.427, P = 0.009), and positively correlated with NYHA class (Spearman’s r = 0.348, P = 0.037) (Figure 5).

4 Discussion

Physiological AVD dynamically varies according to exercise and sympathetic tone changes, and plays a key role in optimal atrial contribution to ventricular filling. A previous study reported reduction in optimal AVD with physiological exercise in patients with CHF who underwent CRT. Furthermore, BiV pacing with a programmable RAAVD translated into a 10% improvement in exercise capacity.[26] This
Table 2. Comparison between standard BiV and RAAVD LUV pacing group.

| Variables                  | Standard BiV pacing group (n = 36) | RAAVD LUV pacing group (n = 36) | P value |
|----------------------------|-----------------------------------|----------------------------------|---------|
| Average follow-up time, month | 13.3 ± 8.6                        | 13.7 ± 8.4                       | 0.842   |
| Time consuming for optimization, min | 50 ± 8                            | 21 ± 5                           | <0.001  |
| Device longevity, yrs        | 3.7 ± 0.2                         | 6.9 ± 0.3                        | <0.001  |
| Optimized AVD, ms            | 110.3 ± 8.1                       | 128.1 ± 9.8                      | <0.001  |
| NYHA class                   | 2.56 ± 0.73                       | 2.47 ± 0.70                      | 0.422   |
| II                          | 21 (58.3%)                        | 24 (66.7%)                       | 0.465   |
| III                         | 10 (27.8%)                        | 9 (25%)                          | 0.789   |
| IV                          | 5 (13.9%)                         | 3 (8.3%)                         | 0.355   |
| V-V/R delay, ms             | 23.9 ± 7.7                        | 19.6 ± 7.3                       | 0.018   |
| QRS complex duration, ms    | 138 ± 10                          | 132 ± 9.8                        | 0.012   |
| LADD, mm                    | 38.3 ± 6.6                        | 36.1 ± 6.2                       | 0.149   |
| LVDD, mm                    | 65.8 ± 9.2                        | 62.2 ± 8.8                       | 0.094   |
| LVEF, %                     | 0.39 ± 0.06                       | 0.41 ± 0.09                      | 0.234   |
| MRA, cm²                    | 2.5 ± 1.3                         | 1.9 ± 1.1                        | 0.038   |
| AVVTI, cm                   | 21.4 ± 2.1                        | 22.7 ± 2.2                       | 0.012   |
| E/A Pd, ms                  | 198 ± 67                          | 186 ± 60                         | 0.426   |
| IVMD, ms                    | 68.3 ± 14.2                       | 60.7 ± 13.3                      | 0.022   |
| Ts-SD12, ms                 | 92 ± 26                           | 81 ± 24                          | 0.066   |
| 6MWT, m                     | 563 ± 81                          | 597 ± 85                         | 0.087   |
| Average annual cost, 10000 RMB | 2.16 ± 0.2                      | 1.32 ± 0.1                       | <0.001  |
| Hospital readmission        | 11 (30.56%)                       | 10 (27.78%)                      | 0.795   |
| Mortality                   | 4 (11.11%)                        | 3 (8.33%)                        | 0.5     |

Data were presented as mean ± SD or n (%). AVD: atrioventricular delay; AVVTI: Aortic velocity-time integral; BiV: biventricular; E/A Pd: E/A procedure duration; LADD: left atrial diameter; LUV: left univentricular; LVDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; IVMD: Interventricular mechanical delay time; MRA: area of the mitral regurgitation; NYHA: New York Heart Association; RAAVD: rate adaptive atrio-ventricular delay; Ts-SD12: standard deviation of time intervals of the 12 LV segments; 6MWT: 6-minute walk test.

Figure 1. The comparison between QRS complex pre- and post-operation. A patient with CHF was implanted with a dual-chamber pacemaker (Relia RED01, Medtronic, Inc., Minneapolis, MN, USA). (A): Pre-CRT (CLBBB, QRS duration was 200 ms under intrinsic atrioventricular conduction); (B): post-LUV pacing with RAAVD (QRS duration was 137 ms). CHF: congestive heart failure; CRT: cardiac resynchronization therapy; LUV: left univentricular; RAAVD: rate adaptive atrio-ventricular delay; Rs-SD5 (Tracking index) indicated that programming a fixed and short AVD for CRT, which abolishes the physiological AVD of the AVN, impaired physiological AV conduction. In this study, we developed an algorithm to preserve the physiological AVD of the AVN, and to achieve CRT with LUV pacing. Left-sided AVD automatically tracks physiological AVD by using an
Figure 2. QRS complex morphology at 5 different HR. (A): At average HR of 60 bpm, S/R ratio was 3.29; (B): at average HR of 70 beats/min, S/R ratio was 3.55; (C): at average HR of 80 beats/min, S/R ratio was 1.25; (D): at average HR of 90 beats/min, S/R ratio was 2.18; (E): at average HR of 100 beats/min, S/R ratio was 2.2. S/R ratio of five segments of HR was 2.49 ± 0.93, tracking index $[RS_{SD5}]$ was 0.93 for this patient. HR: heart rate.

Figure 3. The comparison between Ts-SD12 pre- and post-RAAVD LUV pacing. Bull eye view of real-time three-dimensional echocardiography showed that Ts-SD12 improved 12 months post-RAAVD LUV pacing. (A): Ts-SD12 was 92 ms pre- RAAVD LUV pacing; (B): Ts-SD12 was 70 ms 12 months post-RAAVD LUV pacing. LUV: left univentricular; RAAVD: rate adaptive atrio-ventricular delay.

Figure 4. Chest X-ray pre- and one year post-PM implantation. (A): Pre-PM implantation, chest X-ray showed LV dilated. CTR was 56%, LVDD: 69 mm. (B): 12 months post-PM implantation, great reduction in ventricular size, the CTR decreased from 0.56 to 0.49, LVDD decreased from 69 mm to 53 mm. CRT: cardiac resynchronization therapy; CTR: cardiothoracic ratio; LV: left ventricular; LVDD: left ventricular diastolic diameter; PM: pacemaker.
RAAVD algorithm to allow fusion, with intrinsic conduction from the normal right bundle branch. Therefore, RAAVD LUV pacing algorithms may be more physiological than those of standard BiV pacing. Furthermore, RAAVD LUV pacing eliminates RV pacing, thereby decreasing the risk of heart failure and atrial fibrillation.[27,28] Moreover, RAAVD LUV pacing increases device longevity, as it is not necessary to pace the RV. This decreases the average annual cost of CRT.

RV pacing is a component of standard BiV pacing, in which RV activation is delayed more than in physiological activation. This results in a longer QRS duration, which is associated with mechanical dyssynchrony, decreased cardiac function, and higher mortality.[29] Our results showed that RAAVD LUV pacing can shorten the QRS duration more than with standard BiV pacing. This indicated that RAAVD algorithms can accurately track physiological AVD and enable fusion of intrinsic right bundle conduction with paced LV conduction. Thus, the changes in fusion and QRS duration that result from fixed AVD and varying intrinsic conduction would be resolved. This may explain the results of previous studies showing that fusion was not established in LUV pacing with fixed AVD, and that LUV pacing is not superior to BiV pacing.[30,31]

Interval optimization plays a key role in improving hemodynamic effects in standard BiV pacing; however, it is time-consuming and difficult to achieve individualization and dynamic optimization.[32,33] In LUV pacing with RAAVD, the intrinsic AVD is physiologic and optimal, and there is no need for dynamic optimization. Moreover, left-sided AVD automatically tracks physiological AVD by using an RAAV algorithm. Therefore, RAAVD LUV pacing can achieve dynamic optimization of AVD. Adaptation to physiological alterations during exercise and sympathetic tone changes thereby restore the optimal atrial contribution to ventricular filling. Theoretically, the efficacy of dynamic optimization in LUV pacing is determined by the accuracy of the RAAVD algorithm, which tracks physiological AVD under varying HR. The midpoint (average) between the maximum (R-wave) and minimum (S-wave) amplitude of the QRS complex in lead V1 [(R-V1 + S-V1)/2] has been previously used to characterize the degree of fusion between LUV-paced and intrinsic excitations. Furthermore, with progressive shortening of the programmed AV interval, the QRS (mainly in lead V1) changes from an LBBB- (S/R > 1) to an RBBB-like (S/R < 1) morphology at the shortest AV interval under LUV pacing.[22,23] This indicates that deviation of the S/R ratio may sensitively indicate the degree of fusion at varying HRs, and can evaluate the accuracy of an RAAVD algorithm. This study is the first to describe a tracking index (RS/R-SD5) for use in evaluating the accuracy of an RAAVD algorithm for tracking physiological AVD at varying HRs in LUV pacing. The results of our study showed a significantly negative correlation between RS/R-SD5 and improved LVEF (ΔLVEF), indicating that RS/R-SD5 may be a valuable predictor of response to CRT in LUV pacing.

Recent studies have shown that an adaptive CRT LUV pacing algorithm may improve the response to CRT by 12%.[34,35] The accuracy of physiologic AVD tracking and the comparison between adaptive CRT and an RAAVD LUV pacing algorithm require further investigation.

In summary, RAAVD LUV pacing can preserve the physiological AV conduction of the AVN, and can restore physiological activation of the RV. The result is more physiological and beneficial than standard BiV pacing, thereby improving the response to CRT. However, several variables did not show differences between the two groups, which may be due to the relatively small sample size and short follow-up. Therefore, a randomized, multicenter, double-blind, controlled clinical study is needed to confirm our findings. The novel algorithms for tracking physiological AVD in LUV pacing will contribute to research and development of new pacemakers. This may even challenge the requirement for 100% BiV pacing in traditional CRT.[36]

In conclusion, LUV pacing achieved CRT by using an RAAVD algorithm. This preserved the physiological AV conduction of the AVN, and was more physiological than standard BiV pacing, at least as effective as standard BiV pacing, and decreased the average annual cost of CRT.
Acknowledgments

This study was supported by three grants from National Natural Science Foundation of China (81360044), Yunnan Science and Technology Committee (2013FB133 and Yunnan province National Science Foundation (2013FZ054). The authors declare no conflict of interest regarding.

References

1. Stewart S, Machtyre K, Capewell S, et al. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003; 89: 49–53.
2. Remme EW, Niederer S, Gjesdal O, et al. Factors determining the magnitude of the pre-ejection leftward septal motion in left bundle branch block. European 2016; 18: 1905–1913.
3. Strik M, Regoli F, Auricchio A, et al. Electrical and mechanical ventricular activation during left bundle branch block and resynchronization. J Cardiovasc Transl Res 2012; 5: 117–126.
4. Kazemisaeid A, Rezvanfard M, Sadeghian H, et al. Comparison between tissue doppler imaging (TDI) and tissue synchronization imaging (TSI) in evaluation of left ventricular dyssynchrony in patients with advanced heart failure. Echo-cardiography 2012; 29: 7–12.
5. Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014; 370: 1694–1701.
6. Lalani GG, Birgersdotter-Gre en U. Cardiac resynchronisation therapy in patients with chronic heart failure. Heart 2015; 101: 1008–1014.
7. European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Brignole M, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). European 2013; 15: 1070–1118.
8. Martin CA, Gajendragadkar PR, Pugh PJ. Unusual cause of poor response to cardiac resynchronization therapy. Heart 2014; 100: 514.
9. De Sisti A, Márquez MF, Tonet J, et al. Adverse effects of long-term right ventricular apical pacing and identification of patients at risk of atrial fibrillation and heart failure. Pacing Clin Electrophysiol 2012; 35: 1035–1043.
10. Ludwig DR, Tanaka H, Friefling M, et al. Further deterioration of LV ejection fraction and mechanical synchrony during RV apical pacing in patients with heart failure and LBBB. J Cardiovasc Transl Res 2013; 6: 425–429.
11. Scharf C, Li P, Muntwyler J, et al. Rate-dependent AV delay optimization in cardiac resynchronization therapy. Pacing Clin Electrophysiol 2005; 28: 279–284.
12. Raffie R, Qamruddin S, Ozhand A, et al. Shortening of atrioventricular delay at increased atrial paced heart rates improves diastolic filling and functional class in patients with biventricular pacing. Cardiovasc Ultrasound 2011; 10: 2.
13. Mokrani B, Lafitte S, Deplagne A, et al. Echocardiographic study of the optimal atrioventricular delay at rest and during exercise in recipients of cardiac resynchronization therapy systems. Heart Rhythm 2009; 6: 972–977.
14. Melzer C, Körber T, Theres H, et al. How can the rate-adaptive atrioventricular delay be programmed in atrioventricular block pacing? Europace 2007; 9: 319–324.
15. Steinberg BA, Wehrenberg S, Jackson KP, et al. Atrioventricular and ventricular-to-ventricular-to-programming in patients with cardiac resynchronization therapy: results from ALTITUDE. J Interv Card Electrophysiol 2015; 44: 279–287.
16. Riedlbauchova L, Kautzner J, Fridl P. Influence of different atrioventricular and interventricular delays on cardiac output during cardiac resynchronization therapy. Pacing Clin Electrophysiol 2005; 28 Suppl 1: S19–S23.
17. Tayal B, Gorcsan J, Delgado-Montero A, et al. Comparative long-term outcomes after cardiac resynchronization therapy in right ventricular paced patients versus native wide left bundle branch block patients. Heart Rhythm 2016; 13: 511–518.
18. Gopi A, Sundar G, Yelagudri S, et al. Atrial synchronous left ventricular only pacing with VDD pacemaker system—a cost effective alternative to conventional cardiac resynchronization therapy. Indian Heart J 2014; 66: 612–616.
19. Pu LJ, Wang Y, Zhao L, et al. Cardiac resynchronization therapy (CRT) with right ventricular sense triggered left ventricular pacing benefits for the hemodynamics compared with standard CRT for chronic congestive heart failure: A crossover study. Cardio 2015; 22: 80–86.
20. Guo T, Li R, Zhang L, et al. Biventricular pacing with ventricular fusion by intrinsic activation in cardiac resynchronization therapy. Int Heart J 2015; 56: 293–297.
21. Van Gelder BM, Bracke FA, Meijer A, et al. The hemodynamic effect of intrinsic conduction during left ventricular pacing as compared to biventricular pacing. J Am Coll Cardiol 2005; 46: 2305–2310.
22. Gianfranchi L, Bettolli K, Pacchioni F, et al. The fusion band in V1: a simple ECG guide to optimal resynchronization? An echocardiographic case report. Cardiovasc Ultrasound 2005; 3: 29.
23. Khaykin Y, Exner D, Birnie D, et al. Adjusting the timing of left-ventricular pacing using electrocardiogram and device electrograms. Europace 2011; 13: 1464–1470.
24. Meluzín J, Novák M, Müllerová J, et al. A fast and simple echocardiographic method of determination of the optimal atrioventricular delay in patients after biventricular stimulation. Pacing Clin Electrophysiol 2004; 27: 58–64.
25. Vanderheyden M, De Backer T, Rivero-Ayerza M, et al. Tailored echocardiographic interventricular delay programming further optimizes left ventricular performance after cardiac resynchronization therapy. Heart Rhythm 2005; 2: 1066–1072.
26. Shanmugam N, Prada-Delgado O, Campos AG, et al. Rate-adaptive AV delay and exercise performance following cardiac resynchronization therapy. Heart Rhythm 2012; 9: 1815–1821.
27 Lee KL, Burnes JE, Mullen TJ, et al. Avoidance of right ventricular pacing in cardiac resynchronization therapy improves right ventricular hemodynamics in heart failure patients. J Cardiovasc Electrophysiol 2007; 18: 497–504.
28 Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med 2007; 357: 1000–1008.
29 Brenyo A, Zaręba W. Prognostic significance of QRS duration and morphology. Cardiol J 2011; 18: 8–17.
30 Boriani G, Kranig W, Donal E, et al. A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. Am Heart J 2010; 159: 1052–1058.
31 Thibault B, Ducharme A, Harel F, et al. Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex ≥ 120 milliseconds. Circulation 2011; 124: 2874–2881.
32 Gras D, Gupta MS, Boulogne E, et al. Optimization of AV and VV delays in the real-world CRT patient population: an International survey on current clinical practice. Pacing Clin Electrophysiol 2009; 32 Suppl 1: S236–S239.
33 Cobb DB, Gold MR. The role of ativoventricular and interventricular optimization for cardiac resynchronization therapy. Card Electrophysiol Clin 2015; 7: 765–779.
34 Daoud GE, Houmsse M. Cardiac resynchronization therapy pacemaker: critical appraisal of the adaptive CRT-P device. Med Devices (Auckl) 2016; 18: 19–25.
35 Starling RC, Krum H, Bril S, et al. Impact of a novel adaptive optimization algorithm on 30-day readmissions: evidence from the adaptive CRT trial. JACC Heart Fail 2015; 3: 565–572.
36 Gasparini M, Galimberti P, Ceriotti C. The importance of increased percentage of biventricular pacing to improve clinical outcomes in patients receiving cardiac resynchronization therapy. Curr Opin Cardiol 2013; 28: 50–54.